omeprazole has been researched along with 5-hydroxymethylomeprazole in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.96) | 18.7374 |
| 1990's | 15 (29.41) | 18.2507 |
| 2000's | 20 (39.22) | 29.6817 |
| 2010's | 14 (27.45) | 24.3611 |
| 2020's | 1 (1.96) | 2.80 |
| Authors | Studies |
|---|---|
| Isoherranen, N; Lutz, JD | 1 |
| Chiba, K; Ishizaki, T; Kobayashi, K; Lee, KH; Shin, SG; Sohn, DR | 1 |
| Andersson, T; Cederberg, C; Regårdh, CG; Skånberg, I | 1 |
| Andersson, T; Lagerström, PO; Lundborg, P; Regårdh, CG; Skånberg, I | 1 |
| Andersson, T; Bodemar, G; Larsson, R; Naesdal, J; Regårdh, CG; Skånberg, I; Walan, A | 1 |
| Bertilsson, L; Chang, M; Dahl, ML; Götharson, E; Sagar, M; Seensalu, R; Tybring, G | 1 |
| Chiba, K; Ishizaki, T; Kamataki, T; Kobayashi, K; Manabe, K; Tani, M | 1 |
| Roots, I; Rost, KL | 1 |
| Amamoto, T; Higuchi, S; Ieiri, I; Irie, S; Kimura, M; Kubota, T; Mamiya, K; Nakamura, K; Nakano, S; Urae, A; Wada, Y; Yoshioka, S | 1 |
| Bertilsson, L; Chang, M; Dahl, ML; Götharson, E; Tybring, G | 1 |
| Balian, JD; Daus, JC; Flockhart, DA; Foxworth, JW; Marinac, JS; Owen, R; Willsie, SK | 1 |
| Bertilsson, L; Böttiger, Y; Tybring, G; Widén, J | 1 |
| Ashton, M; Bertilsson, L; Dinh, XH; Le, DC; Lykkesfeldt, J; Nguyen, DS; Nguyen, TN; Nguyen, VH; Svensson, US; Trinh, NH | 1 |
| Matuszewski, BK; Woolf, EJ | 1 |
| Edwards, DJ; Kovacs, P; Lalka, D; Scheiwe, WM; Stoeckel, K | 1 |
| Ashton, M; Bertilsson, L; Hai, TN; Mihara, K; Svensson, US; Tybring, G | 1 |
| Tassaneeyakul, W; Vannaprasaht, S; Yamazoe, Y | 1 |
| Farrán, R; García-Encina, G; Martínez, L; Puig, S | 1 |
| Abelö, A; Andersson, TB; Antonsson, M; Naudot, AK; Skånberg, I; Weidolf, L | 1 |
| Huang, SL; Shu, Y; Wang, LS; Wang, W; Xiao, WM; Zhou, HH | 1 |
| Chow, AH; Chow, MS; Tomlinson, B; Waye, MM; Yin, OQ | 1 |
| Lang, CC; Lee, TC; Mohamed, Z; Mustafa, AM; Pang, YS; Wong, LP; Yang, YS | 1 |
| Bertilsson, L; Kim, PS; Lee, DH; Park, CS; Roh, HK; Sagar, M; Seensalu, R; Tybring, G | 1 |
| Frerichs, VA; Haas, CE; Zaranek, C | 1 |
| Ishizawa, Y; Sasaki, M; Takahata, T; Tateishi, T; Yasui-Furukori, N | 1 |
| Bravo, E; Galera, R; Martínez-Lozano, C; Pérez-Ruiz, T; Sanz, A | 1 |
| Naidong, W; Song, Q | 1 |
| Hofmann, U; Klotz, U; Leodolter, A; Malfertheiner, P; Schaeffeler, E; Schwab, M; Treiber, G | 1 |
| Cervantes, R; González, H; Hoyo-Vadillo, C; Mata, N; Ortiz, AC; Ramírez-Mayans, J; Rincón, V; Romero, E; Sosa, C; Venturelli, CR; Zarate, F | 1 |
| Blomberg, LG; Marlin, N; Olsson, J; Stegander, F; Wan, H | 1 |
| Bottoli, CB; Collins, CH; Ribani, M | 1 |
| Beltrán, L; Henao, J; Isaza, C; Martínez, JH; Sepúlveda Arias, JC | 1 |
| Hayakari, M; Niioka, T; Sugawara, K; Sugimoto, K; Tateishi, T; Uno, T | 1 |
| Chen, Y; Fan, L; Hu, DL; Huang, RX; Huang, YF; Wang, D; Wang, G; Wang, LS; Zhang, W; Zhou, HH | 1 |
| Blomberg, LG; Olsson, J | 1 |
| Chen, BL; Chen, Y; Fan, L; Hu, DL; Li, Q; Li, YL; Ouyang, DS; Tan, ZR; Tu, JH; Wang, D; Wang, LS; Zhang, W; Zhou, HH | 1 |
| Eom, SO; Jin, SK; Kang, TS; Kim, JI; Lee, HJ; Roh, J | 1 |
| Bertilsson, L; Eliasson, E; Masquelier, M; Ostervall, J; Otto, S; Rosenborg, S; Stenberg, M; Yue, QY | 1 |
| Shiohira, H; Tateishi, T; Uno, T; Yasui-Furukori, N | 1 |
| Baldwin, RM; Capparelli, EV; Ingelman-Sundberg, M; Lawson, EB; Ma, JD; Rosenborg, S; Wu, JC; Yim, DS; Yin, OQ | 1 |
| Babaoglu, MO; Balamtekin, N; Baysoy, G; Bozkurt, A; Demir, H; Gumus, E; Karaca, O; Uslu, N; Yasar, U; Yuce, A | 1 |
| Kim, DH; Oh, KS; Park, SJ; Shin, JG; Shinde, DD | 1 |
| Li, XY; Li, YP; Liu, YN; Yang, YZ; Yuan, M; Zhu, JB | 1 |
| Keyhanfar, F; Kobarfard, F; Motevalian, M; Noubarani, M | 1 |
| Brosen, K; Noehr-Jensen, L; Pedersen, RS | 1 |
| Ahmad, L; Iqbal, Z; Nasir, F; Nazir, S; Shah, Y | 1 |
| Ghahremani, MH; Payan, M; Rouini, MR; Tahvilian, R; Tajik, N | 1 |
| Ahmad, L; Ahmad, S; Iqbal, Z; Nazir, S | 1 |
| Hunter, C; MacLachlan, J; McNaughtan, ML; Pahl, O; Roberts, J | 1 |
| Ahmad, L; Iqbal, Z; Khan, A; Khan, I; Khan, MI; Khuda, F; Nazir, S; Shah, Y | 1 |
| Ferlini Agne, G; Franklin, S; Knych, H; Somogyi, AA; Sykes, B | 1 |
1 review(s) available for omeprazole and 5-hydroxymethylomeprazole
| Article | Year |
|---|---|
Comparative pharmacokinetics of Omeprazole and its metabolites in poor and extensive metabolizer Pakistani healthy volunteers and a review of different studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Genotype; Healthy Volunteers; Humans; Omeprazole | 2018 |
17 trial(s) available for omeprazole and 5-hydroxymethylomeprazole
| Article | Year |
|---|---|
High-dose omeprazole: use of a multiple-dose study design to assess bioequivalence and accuracy of CYP2C19 phenotyping.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Female; Humans; Male; Mixed Function Oxygenases; Omeprazole; Pharmacogenetics; Phenotype; Therapeutic Equivalency; Time Factors | 1999 |
Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Beverages; Citrus; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Humans; Male; Mixed Function Oxygenases; Omeprazole; Time Factors | 2000 |
Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Cross-Over Studies; Cytochrome P-450 CYP2C19; Enzyme Inhibitors; Gene Dosage; Humans; Hydroxylation; Male; Mephenytoin; Mixed Function Oxygenases; Omeprazole; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Reference Values | 2004 |
Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Female; Gastric Acidity Determination; Gastrins; Genotype; Humans; Hydrogen-Ion Concentration; Korea; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Phenotype; Stomach Diseases | 2004 |
Analysis of omeprazole, midazolam and hydroxy-metabolites in plasma using liquid chromatography coupled to tandem mass spectrometry.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aryl Hydrocarbon Hydroxylases; Calibration; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Humans; Injections, Intravenous; Mass Spectrometry; Midazolam; Mixed Function Oxygenases; Omeprazole; Reproducibility of Results; Time Factors | 2005 |
Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Esomeprazole; Female; Gastroesophageal Reflux; Genotype; H(+)-K(+)-Exchanging ATPase; Half-Life; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Time Factors | 2005 |
Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; American Indian or Alaska Native; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Biotransformation; Chromatography, High Pressure Liquid; Colombia; Cytochrome P-450 CYP2C19; Female; Gene Frequency; Genetics, Population; Genotype; Humans; Hydroxylation; Liver; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Phenotype; Polymorphism, Genetic | 2007 |
Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Monitoring; Female; Genotype; Humans; Hydroxylation; Injections, Intravenous; Linear Models; Male; Mixed Function Oxygenases; Omeprazole; Time Factors | 2007 |
Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Area Under Curve; Artemisia; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Combinations; Drugs, Chinese Herbal; Genotype; Herb-Drug Interactions; Humans; Hydroxylation; Male; Omeprazole; Plants, Medicinal; Safrole | 2007 |
Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Clopidogrel; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Genotype; Humans; Hydroxylation; Male; Omeprazole; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Spectrophotometry, Ultraviolet; Sulfoxides; Ticlopidine; Young Adult | 2009 |
CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Alleles; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2C19; Female; Half-Life; Haplotypes; Humans; Korea; Male; Omeprazole; Polymorphism, Single Nucleotide; Young Adult | 2009 |
Clinically significant CYP2C inhibition by noscapine but not by glucosamine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anticoagulants; Antitussive Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Drug Interactions; Female; Glucosamine; Humans; Losartan; Male; Middle Aged; Noscapine; Omeprazole; Phenotype; Warfarin; Young Adult | 2010 |
Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Male; Models, Biological; Omeprazole; Phenotype; White People; Young Adult | 2012 |
Variation in omeprazole pharmacokinetics in a random Iranian population: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Area Under Curve; Biotransformation; Chromatography, High Pressure Liquid; Half-Life; Humans; Hydroxylation; Iran; Male; Metabolic Clearance Rate; Omeprazole; Phenotype; Pilot Projects; Proton Pump Inhibitors; Tandem Mass Spectrometry; Young Adult | 2012 |
Pharmacokinetics of omeprazole and its metabolites in three phases of menstrual cycle.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Area Under Curve; Biotransformation; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Female; Follicular Phase; Healthy Volunteers; Humans; Luteal Phase; Menstrual Cycle; Menstruation; Metabolic Clearance Rate; Omeprazole; Proton Pump Inhibitors; Spectrophotometry, Ultraviolet | 2015 |
Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alleles; Anti-Ulcer Agents; Cytochrome P-450 CYP2C19; Female; Genotype; Humans; Hydroxylation; Iran; Male; Middle Aged; Omeprazole; Phenotype; Polymorphism, Genetic; Proton Pump Inhibitors; Sex Factors; White People; Young Adult | 2014 |
Variation in pharmacokinetics of omeprazole and its metabolites by gender and CYP2C19 genotype in Pakistani male and female subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Area Under Curve; Biotransformation; Cytochrome P-450 CYP2C19; Female; Heterozygote; Homozygote; Humans; Hydroxylation; Linear Models; Male; Metabolic Clearance Rate; Models, Biological; Omeprazole; Pakistan; Pharmacogenetics; Phenotype; Proton Pump Inhibitors; Sex Factors; Young Adult | 2016 |
33 other study(ies) available for omeprazole and 5-hydroxymethylomeprazole
| Article | Year |
|---|---|
Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole.
Topics: Dextromethorphan; Humans; Microsomes, Liver; Omeprazole; Predictive Value of Tests | 2012 |
Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Humans; Hydroxylation; Korea; Male; Mephenytoin; Omeprazole | 1992 |
Pharmacokinetics of various single intravenous and oral doses of omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Biological Availability; Dose-Response Relationship, Drug; Humans; Injections, Intravenous; Male; Omeprazole | 1990 |
The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Biological Availability; Biotransformation; Feces; Half-Life; Humans; Injections, Intravenous; Male; Omeprazole | 1990 |
Pharmacokinetics of [14C]omeprazole in patients with impaired renal function.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Blood Proteins; Female; Humans; Kidney Failure, Chronic; Kinetics; Male; Mathematics; Middle Aged; Omeprazole | 1986 |
Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cohort Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Female; Gastrins; Heterozygote; Humans; Male; Mixed Function Oxygenases; Omeprazole; Phenotype; Polymorphism, Genetic; Sweden; Tablets, Enteric-Coated | 1995 |
Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Humans; Hydroxylation; In Vitro Techniques; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Oxidation-Reduction; Sulfur | 1993 |
Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Genetic Variation; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Phenotype; Proton Pump Inhibitors | 1996 |
Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alleles; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Exons; Female; Genotype; Half-Life; Humans; Japan; Male; Middle Aged; Mixed Function Oxygenases; Mutation; Omeprazole | 1996 |
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alleles; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Female; Genotype; Humans; Hydroxylation; Male; Mephenytoin; Middle Aged; Mixed Function Oxygenases; Molecular Probes; Omeprazole; Pharmacogenetics; Phenotype; Sweden; White People | 1995 |
Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aryl Hydrocarbon Hydroxylases; Black People; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Genotype; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Phenotype; Reference Values | 1996 |
Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Female; Humans; Hydroxylation; Isomerism; Liver; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Sweden | 1997 |
Artemisinin induces omeprazole metabolism in human beings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antimalarials; Area Under Curve; Artemisinins; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Humans; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Reference Values; Sesquiterpenes; Time Factors | 1998 |
Simultaneous determination of omeprazole and 5'-hydroxyomeprazole in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Humans; Mass Spectrometry; Omeprazole; Reference Standards; Reproducibility of Results; Sensitivity and Specificity | 1998 |
Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antimalarials; Area Under Curve; Artemisinins; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Inhibitors; Humans; Male; Mixed Function Oxygenases; Omeprazole; Sesquiterpenes; Stereoisomerism; Structure-Activity Relationship | 1999 |
Validation of an automated liquid chromatographic method for omeprazole in human plasma using on-line solid-phase extraction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Automation; Chromatography, High Pressure Liquid; Drug Stability; Flow Injection Analysis; Humans; Omeprazole; Quality Control; Reproducibility of Results | 1999 |
Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Humans; In Vitro Techniques; Isoenzymes; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Stereoisomerism | 2000 |
Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulphone.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antibodies, Monoclonal; Aryl Hydrocarbon Hydroxylases; Asian People; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole | 2000 |
Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Female; Gene Frequency; Humans; Malaysia; Male; Mixed Function Oxygenases; Omeprazole; Phenotype; Polymerase Chain Reaction; Polymorphism, Genetic | 2004 |
The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Aging; Alleles; Analysis of Variance; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Genotype; Heterozygote; Homozygote; Humans; Linear Models; Mixed Function Oxygenases; Mutation; Omeprazole | 2005 |
Determination of omeprazole, hydroxyomeprazole and omeprazole sulfone using automated solid phase extraction and micellar electrokinetic capillary chromatography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Electrophoresis, Capillary; Micelles; Omeprazole; Pharmaceutical Preparations | 2006 |
Analysis of omeprazole and 5-OH omeprazole in human plasma using hydrophilic interaction chromatography with tandem mass spectrometry (HILIC-MS/MS)--eliminating evaporation and reconstitution steps in 96-well liquid/liquid extraction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, Liquid; Humans; Mass Spectrometry; Omeprazole; Reproducibility of Results; Sensitivity and Specificity | 2006 |
Metabolism of omeprazole after two oral doses in children 1 to 9 months old.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Gene Frequency; Humans; Infant; Infant, Newborn; Male; Mexico; Mixed Function Oxygenases; Omeprazole; Phenotype | 2005 |
Enantiomeric separation of omeprazole and its metabolite 5-hydroxyomeprazole using non-aqueous capillary electrophoresis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cyclodextrins; Electrophoresis, Capillary; Omeprazole; Reproducibility of Results; Stereoisomerism | 2006 |
Validation of chromatographic methods: evaluation of detection and quantification limits in the determination of impurities in omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drug Contamination; Omeprazole; Uncertainty | 2007 |
Enantioseparation of omeprazole and its metabolite 5-hydroxyomeprazole using open tubular capillary electrochromatography with immobilized avidin as chiral selector.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Avidin; Capillary Electrochromatography; Omeprazole; Reproducibility of Results; Stereoisomerism | 2008 |
Chiral assay of omeprazole and metabolites and its application to a pharmacokinetics related to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Genotype; Humans; Omeprazole; Sensitivity and Specificity | 2011 |
Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Aryl Hydrocarbon Hydroxylases; Biotransformation; Child; Child, Preschool; Cytochrome P-450 CYP2C19; Female; Gene Frequency; Genetic Association Studies; Hospitals, Pediatric; Humans; Lansoprazole; Male; Omeprazole; Pharmacogenetics; Polymorphism, Genetic; Proton Pump Inhibitors; Turkey | 2012 |
High-sensitivity liquid chromatography-tandem mass spectrometry for the simultaneous determination of five drugs and their cytochrome P450-specific probe metabolites in human plasma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Caffeine; Chromatography, Liquid; Cytochrome P-450 Enzyme System; Drug Stability; Humans; Imidazoles; Linear Models; Liquid-Liquid Extraction; Losartan; Omeprazole; Pharmaceutical Preparations; Reproducibility of Results; Tandem Mass Spectrometry; Tetrazoles; Theophylline | 2012 |
[Effect of high altitude hypoxia on the activity and protein expression of CYP2C9 and CYP2C19].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Altitude; Animals; Cytochrome P-450 Enzyme System; Enzyme Activation; Female; Hypoxia; Male; Omeprazole; Phenytoin; Rats; Rats, Sprague-Dawley | 2012 |
Inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19*17 allele.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alleles; Aryl Hydrocarbon Hydroxylases; Contraceptives, Oral; Cytochrome P-450 CYP2C19; Female; Gene Expression; Genotype; Heterozygote; Humans; Middle Aged; Mutation; Omeprazole; Proton Pump Inhibitors; Young Adult | 2013 |
Identification of the acid-induced degradation products of omeprazole and 5-hydroxyomeprazole by high-resolution mass spectrometry.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acids; Anti-Ulcer Agents; Mass Spectrometry; Omeprazole; Wastewater; Water Pollutants, Chemical | 2018 |
Identification and kinetics of microsomal and recombinant equine liver cytochrome P450 enzymes responsible for in vitro metabolism of omeprazole.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Horses; Humans; Kinetics; Liver; Microsomes, Liver; Omeprazole; Sulfones | 2023 |